Search

Displaying results 4951 - 4960 of 8698 in total
  1. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

  2. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. … Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    JTC-801 free base

    go.drugbank.com/drugs/DB17033
    Experimental

    An antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]

  4. Drug

    Suvodirsen

    go.drugbank.com/drugs/DB17940
    Investigational

    Suvodirsen is an antisense oligonucleotide that has been investigated for the treatment of Duchenne muscular dystrophy.

  5. Drug

    Enviomycin

    go.drugbank.com/drugs/DB08993
    Experimental

    It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  6. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    It is an alpha2-adrenergic agonist.

    Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists
  7. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … Furthermore, the antibodies produced were capable of inhibiting the binding of SARS-CoV-2 to the ACE2 receptor, which is thought to be critical for host cell entry.

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. … Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes.

  9. Target

    Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1

    go.drugbank.com/bio_entities/BE0004522
    TargetTransporterHumans

    Inositol 1,4,5-trisphosphate-gated calcium channel that, upon inositol 1,4,5-trisphosphate binding, mediates calcium release from the endoplasmic reticulum (ER) (PubMed:10620513, PubMed:27108797). Undergoes conformational changes upon li...

    Synonyms: IP3 receptor isoform 1, Type 1 InsP3 receptor
  10. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates